文献速递脑血管病

HERMES-24评分在晚时间窗大血管闭塞治疗结局预测中的验证

Validation of the HERMES-24 Score for Outcome Prediction Post Large Vessel Occlusion Treatment in Later Time Window.
PubMed 文献 · Neurology · 2025-07-03

本研究基于6项随机试验的患者水平荟萃分析,纳入435例晚时间窗(最后正常时间>6小时)前循环大血管闭塞且小梗死核心患者,评估HERMES-24评分对90天结局的预测能力。结果显示该评分在血管内治疗组和对照组均能高度预测90天mRS≤2、≤3、序贯mRS及死亡率,但需在真实临床环境中进一步验证。

要点

  • HERMES-24评分可预测晚时间窗大血管闭塞患者90天功能结局和死亡。
  • 预测能力在血管内治疗组和对照组中均较高,不受干预影响。
  • 该评分需在真实世界临床环境中进一步验证适用性。

核心结论

  • HERMES-24评分对晚时间窗前循环大血管闭塞且小梗死核心患者的90天结局具有高度预测能力,且不依赖于是否接受血管内治疗。

研究设计与样本

  • 研究数据来自6项血管内治疗随机试验的患者水平荟萃分析(最后已知正常时间>6小时),纳入435例患者,排除同时属于HERMES协作数据集者。
  • HERMES-24评分计算为患者年龄/10与随机化后24小时NIHSS评分之和。

主要发现

  • 在血管内治疗组(n=223),HERMES-24评分预测90天mRS≤2、≤3、序贯mRS及死亡率的c-statistic(95%CI)分别为0.917(0.875-0.944)、0.895(0.853-0.938)、0.820(0.745-0.891)、0.849(0.776-0.922)。
  • 在对照组(n=212),相应c-statistic(95%CI)分别为0.921(0.872-0.969)、0.879(0.827-0.930)、0.805(0.746-0.852)、0.805(0.738-0.871)。

关键数值与推荐

  • HERMES-24评分=年龄/10+随机化后24小时NIHSS评分。
  • 患者中位年龄71岁,48.5%为男性,中位发病至随机化时间654分钟(IQR 516-849),中位基线NIHSS评分16(IQR 13-21)。

临床怎么用

  • 对于晚时间窗(最后正常时间>6小时)前循环大血管闭塞且小梗死核心的患者,可使用HERMES-24评分辅助预测90天功能结局和死亡风险。

局限性

  • 研究基于随机试验数据,需在真实世界临床环境中进一步验证该评分对所有晚时间窗大血管闭塞患者的适用性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: The Highly Effective Reperfusion Evaluated in Multiple Endovascular Stroke Trials (HERMES)-24 score is highly predictive of outcomes after anterior circulation large vessel occlusion (LVO) treatment, irrespective of intervention in the early time window. Recent evidence has further broadened the eligibility of endovascular therapy (EVT) to patients with late presentation or unwitnessed onset including those with stroke-on-awakening. We aimed to investigate the prediction ability of the HERMES-24 score in patients with anterior circulation LVO and small ischemic core presenting in the late time window from last seen normal. METHODS: Data are from the Analysis of Pooled Data from Randomized Studies of Thrombectomy More Than 6 Hours After Last Known Well collaboration, a patient-level meta-analysis of 6 randomized trials of EVT beyond 6 hours after last known well, with an enrollment period from September 2014 to March 2019. Patients who were also part of the HERMES collaboration data set were excluded from the analyses. The HERMES-24 score was calculated as the sum of the patient's age/10 and NIH Stroke Scale (NIHSS) score at 24 hours after randomization. The predictive ability of the score for a 90-day outcome (modified Rankin Scale [mRS] scores ≤2 and ≤3, ordinal mRS score, and mortality) was investigated. RESULTS: Among 435 patients (48.5% men, median age 71 years), the median onset-to-randomization time was 654 (interquartile range 516-849) minutes and the median baseline NIHSS score was 16 (interquartile range 13-21). The HERMES-24 score was predictive of 90-day mRS scores ≤2 and ≤3, ordinal mRS score, and mortality in both the EVT arm (n = 223, c-statistic [95% CI] 0.917 [0.875-0.944], 0.895 [0.853-0.938], 0.820 [0.745-0.891], and 0.849 [0.776-0.922], respectively) and the control arm (n = 212, c-statistic [95% CI] 0.921 [0.872-0.969], 0.879 [0.827-0.930], 0.805 [0.746-0.852], and 0.805 [0.738-0.871], respectively). DISCUSSION: The HERMES-24 score was highly predictive of 90-day outcome among patients with stroke due to LVO and small ischemic core for those presenting in the late time window, irrespective of intervention. This score must be further validated in a real-world clinical setting if it is applicable to all patients with LVO admitted in late time windows.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Tanaka K, Brown S, Albers GW, et al. Validation of the HERMES-24 Score for Outcome Prediction Post Large Vessel Occlusion Treatment in Later Time Window. Neurology. 2025. PMID: 40609063. doi:10.1212/WNL.0000000000213796

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。